The Insider, Abg Management Ltd Unloaded 70,721 Shares of Sorrento Therapeutics, Inc. (SRNE); S&W Seed Company NV (SANW) Shorts Decreased By 6.44%

February 7, 2018 - By rebbecca

Abg Management Ltd, an insider of Sorrento Therapeutics Inc made a sale of 70,721 shares of the corporation with market value of about $566,037 U.S. Dollars at an average 8.0 U.S. Dollars per share. The date of trade was 07-02-2018, and it was disclosed in a SEC-filed filing, which you can find here. Abg Management Ltd right now owns 7.75 million shares which are equivalent to around 10%+ of the California-Company’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding).

S&W Seed Company NV (NASDAQ:SANW) had a decrease of 6.44% in short interest. SANW’s SI was 653,800 shares in February as released by FINRA. Its down 6.44% from 698,800 shares previously. With 76,000 avg volume, 9 days are for S&W Seed Company NV (NASDAQ:SANW)’s short sellers to cover SANW’s short positions. The SI to S&W Seed Company NV’s float is 6.56%. The stock decreased 3.07% or $0.12 during the last trading session, reaching $3.95. About 53,973 shares traded. S&W Seed Company (NASDAQ:SANW) has declined 4.21% since February 7, 2017 and is downtrending. It has underperformed by 20.91% the S&P500.

Among 7 analysts covering S&W Seed Company (NASDAQ:SANW), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. S&W Seed Company had 9 analyst reports since August 30, 2015 according to SRatingsIntel. The stock has “Buy” rating by B. Riley & Co on Friday, September 15. The rating was initiated by Noble Financial on Wednesday, January 24 with “Buy”. PiperJaffray downgraded S&W Seed Company (NASDAQ:SANW) on Thursday, May 11 to “Neutral” rating. The firm earned “Overweight” rating on Thursday, September 17 by Piper Jaffray. The company was downgraded on Friday, September 15 by Craig Hallum. The stock of S&W Seed Company (NASDAQ:SANW) has “Hold” rating given on Friday, October 16 by TheStreet. Zacks maintained S&W Seed Company (NASDAQ:SANW) rating on Sunday, August 30. Zacks has “Buy” rating and $8 target.

Investors sentiment decreased to 0.73 in 2017 Q3. Its down 0.04, from 0.77 in 2017Q2. It worsened, as 5 investors sold S&W Seed Company shares while 10 reduced holdings. 5 funds opened positions while 6 raised stakes. 12.40 million shares or 9.49% more from 11.33 million shares in 2017Q2 were reported. Morgan Stanley holds 2,311 shares. Vertex One Asset owns 34,065 shares. Smith Moore & reported 0.01% stake. Janney Montgomery Scott Limited Liability has 10,400 shares for 0% of their portfolio. Royal Retail Bank Of Canada holds 12 shares. Bancorporation Of America De invested 0% in S&W Seed Company (NASDAQ:SANW). Wynnefield reported 4.01M shares. Vanguard Grp Incorporated Incorporated reported 0% in S&W Seed Company (NASDAQ:SANW). Shufro Rose & Ltd Liability Corp has 14,500 shares for 0% of their portfolio. Rmb Management Ltd Llc has invested 0.03% in S&W Seed Company (NASDAQ:SANW). Geode Cap Mgmt Lc has 47,917 shares for 0% of their portfolio. Barclays Pcl has 87 shares. Price Michael F holds 1.97% or 4.51M shares. Thomson Horstmann & Bryant Inc has 488,744 shares. Cutter And Brokerage, Missouri-based fund reported 616,840 shares.

S&W Seed Company, an agricultural company, engages in breeding, growing, processing, and selling alfalfa seeds. The company has market cap of $95.95 million. The firm sells its seeds to distributors and dealers in approximately 30 countries worldwide. It currently has negative earnings.

Since August 15, 2017, it had 1 buying transaction, and 2 insider sales for $1.19 million activity. 375,000 shares valued at $1.20M were bought by MFP PARTNERS LP on Tuesday, August 15. Szot Matthew K also sold $3,416 worth of S&W Seed Company (NASDAQ:SANW) on Sunday, October 1.

Investors sentiment decreased to 0.67 in Q3 2017. Its down 0.11, from 0.78 in 2017Q2. It is negative, as 9 investors sold Sorrento Therapeutics, Inc. shares while 12 reduced holdings. 3 funds opened positions while 11 raised stakes. 8.31 million shares or 22.78% less from 10.76 million shares in 2017Q2 were reported. Virtu Financial Limited Liability has invested 0% of its portfolio in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Citigroup owns 4,000 shares or 0% of their US portfolio. Art Advsr Lc reported 123,455 shares or 0.01% of all its holdings. Gofen And Glossberg Ltd Liability Corp Il invested 0% of its portfolio in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). 552,649 are held by Millennium Management Limited Liability. Creative Planning, a Kansas-based fund reported 25,602 shares. Meeder Asset Incorporated holds 0% or 1,917 shares in its portfolio. Renaissance Techs reported 233,563 shares stake. State Street invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Tower Capital Ltd Com (Trc) holds 0% or 2,872 shares in its portfolio. Gagnon Lc holds 31,586 shares. Northern Tru reported 174,327 shares or 0% of all its holdings. Commercial Bank Of Ny Mellon invested in 33,534 shares or 0% of the stock. Wildcat Management Limited Liability Company holds 0.85% or 2.80 million shares in its portfolio. Citadel Advsr Limited Liability Company reported 0% of its portfolio in Sorrento Therapeutics, Inc. (NASDAQ:SRNE).

Since January 23, 2018, it had 0 insider purchases, and 2 selling transactions for $7.54 million activity. ABG Management Ltd had sold 310,000 shares worth $2.37 million. Another trade for 684,288 shares valued at $5.18M was sold by Asia Pacific MedTech (BVI) Ltd.

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company has market cap of $582.99 million. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. It currently has negative earnings. The firm offers resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease.